Equillium, Inc. /
Bioniz Therapeutics, Inc.
Equillium adds Bioniz Therapeutics to its business
- Terms
- Not stated
- Stage
- Agreement signed
What happened
Equillium, Inc. merged its subsidiary with Bioniz Therapeutics, Inc., which continues as a wholly owned subsidiary of Equillium.
Consideration included 5,699,492 shares of Equillium common stock and contingent payments tied to regulatory and commercialization events.
The source
Everything on this page comes from the source below.
Equillium adds Bioniz Therapeutics to its business
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly